Essential Tremor Clinical Trial
Official title:
Penpulimab Plus Chemotherapy With or Without Anlotinib as First-line Therapy for Patients With Advanced Esophageal Squamous Cell Carcinoma (Answer): A Randomized Two-arm Clinical Study
Penpulimab plus chemotherapy with or without Anlotinib as first-line therapy for patients with advanced esophageal squamous cell carcinoma (Answer): A randomized two-arm clinical study.
This is a open-label, phase II study of Penpulimab plus chemotherapy with or without Anlotinib as first-line therapy in subjects With resectable advanced esophageal squamous cell carcinoma. The patients will be divided into two groups. In group A, Penpulimab plus chemotherapy with Anlotinib will be given every 3 weeks for 4-6 cycles in initial stage, then in maintenance treatment, Anlotinib and Penpulimab will be used every 3 weeks until disease progression or intolerance; In group B, Penpulimab plus chemotherapy will be given every 3 weeks for 4-6 cycles in initial stage, then in maintenance treatment, Penpulimab will be used every 3 weeks until disease progression or intolerance; ;
NCT number | NCT05214222 |
Study type | Interventional |
Source | Nanfang Hospital of Southern Medical University |
Contact | wei wang |
Phone | 020-61642136 |
[email protected] | |
Status | Not yet recruiting |
Phase | Phase 2 |
Start date | March 1, 2022 |
Completion date | July 1, 2024 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05381688 -
VIM DBS Respiratory Modulation: N-of-1 Trial
|
||
Recruiting |
NCT05101161 -
Neurofeedback Using Implanted Deep Brain Stimulation Electrodes
|
N/A | |
Terminated |
NCT02678429 -
Atlas Predicted DBS Settings in Essential Tremor
|
Phase 4 | |
Terminated |
NCT02894567 -
Evaluation of Directional Recording and Stimulation Using spiderSTN
|
N/A | |
Completed |
NCT02523807 -
Tremor Monitoring Device
|
N/A | |
Active, not recruiting |
NCT02255929 -
Gamma Knife Radiosurgery for Treatment of Essential Tremor
|
N/A | |
Completed |
NCT02277106 -
Evaluate SAGE-547 in Patients With Essential Tremor
|
Phase 2 | |
Completed |
NCT01223144 -
Decision-making and Emotion Recognition in Essential Tremor
|
N/A | |
Completed |
NCT00906412 -
Ventrointermediate Nucleus (VIM DBS) and Working Memory
|
N/A | |
Completed |
NCT03051178 -
Wearable Sensor for Responsive DBS for ET
|
N/A | |
Recruiting |
NCT03795935 -
Relief From Side Effects: Clinical Use of Electrodes With Direction
|
N/A | |
Recruiting |
NCT04501133 -
Sensory-specific Peripheral Stimulation for Tremor Management
|
N/A | |
Active, not recruiting |
NCT03560622 -
Functional Neuroimaging Feedback for Focused Ultrasound Thalamotomy
|
N/A | |
Completed |
NCT00368199 -
Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes
|
N/A | |
Recruiting |
NCT05106816 -
The Effects of Vibrotactile Stimulation in Patients With Movement Disorders
|
N/A | |
Recruiting |
NCT04720469 -
A Second Magnetic Resonance Guided Focused Ultrasound Thalamotomy for Essential Tremor
|
N/A | |
Completed |
NCT01468948 -
Octanoic Acid for Essential Tremor
|
Phase 1 | |
Recruiting |
NCT04032470 -
Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)
|
||
Completed |
NCT02947841 -
The Effectiveness of Alternating Stimulation in Preventing Tolerance in Essential Tremor Patients
|
N/A | |
Active, not recruiting |
NCT02668146 -
An Efficacy/Safety Study of Perampanel for Reducing Essential Tremor
|
Phase 2 |